Concord Biotech Limited has successfully completed regulatory inspections conducted by two African regulatory authorities at its Unit-II formulation facility.
The Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda conducted the inspection from June 18, 2026 to June 24, 2026. The inspection was concluded successfully without any observations or deficiencies noted in the disclosure.
The company describes this achievement as "a significant milestone in Concord Biotech's global growth journey" that reinforces their commitment to the highest standards of quality and regulatory excellence. This successful inspection strengthens the company's global manufacturing and regulatory footprint, particularly in the African markets represented by Kenya and Uganda.
The disclosure was signed by Paritosh Trivedi, Company Secretary & Compliance Officer (ACS 63623), and submitted to both the National Stock Exchange of India Limited and BSE Limited for information and records.
Financial Impact
No specific financial impact or quantification provided in the disclosure. The significance is strategic and operational in nature, relating to regulatory compliance and market access.